Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
FEBS Lett ; 485(2-3): 135-41, 2000 Nov 24.
Article in English | MEDLINE | ID: mdl-11094155

ABSTRACT

WSL-1/TRAMP (DR3) is a member of the tumour necrosis factor (TNF) receptor superfamily which exhibits effects on NF-kappaB activation and apoptosis. TWEAK, a novel TNF-related molecule, has been proposed as the ligand for this receptor. Utilising both human and murine TWEAK ligand, it is shown that TWEAK and WSL-1/TRAMP do not interact in an in vitro binding assay and that TWEAK binds strongly to cells that do not express WSL-1/TRAMP on the cell surface. Biological activity of TWEAK is also observed in these cells. Finally, cells isolated from WSL-1/TRAMP knockout mice are shown to retain their ability to interact with TWEAK. These results suggest that WSL-1/TRAMP is not the major receptor for TWEAK


Subject(s)
Carrier Proteins/metabolism , Receptors, Tumor Necrosis Factor/metabolism , Animals , Apoptosis , Apoptosis Regulatory Proteins , Cell Line , Cytokine TWEAK , Humans , Interleukin-8/pharmacology , Lymphocytes/metabolism , Mice , Mice, Knockout , NF-kappa B/metabolism , Receptors, Tumor Necrosis Factor/deficiency , Receptors, Tumor Necrosis Factor, Member 25 , Tumor Necrosis Factor-alpha/metabolism , Tumor Necrosis Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...